- A. Health Biotechnology
- Areas of activity
- In vitro diagnostics
Algenex is a private, venture-backed biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics.
Algenex has successfully developed more than 200 molecules (including VLP-based vaccines, monomeric vaccines, diagnostic reagents, enzymes and growth factors) with public and private partners, including several international pharmaceutical companies. The company recently started its foray into human health, aiming to capitalise on the advantages of CrisBio® in the production of vaccines and other high-need pharmaceuticals.
Algenex's first two platforms, TopBac® and CrisBio®, are based on baculovirus expression systems and have demonstrated their ability to transform recombinant protein production through a process that provides almost unlimited and immediate manufacturing scalability, production flexibility, simplicity and high cost-effective versatility.
- Licensing of the rights to use its technology platforms for the production of recombinant proteins, both for the development phase and for commercial purposes;
- Supply of reagents for diagnostic kits or co-development thereof;
- Development of vaccines in collaboration with external partners;
- Licensing of its immunopotentiator molecule for use in veterinary and human vaccines.
Financing, Internationalization and Technological Transformation